Main Article Content
Severe thalssemia patients require blood transfusion with iron chelation daily to improve quality of long life. The cost of this hypertransfusion program was provided by The National Health Security Office (NHSO) base on the year 2006 was 6,660,000 THB per a 30 years patient. Hematopoietic stem cell transplantation (HSCT) is a new alternation way for curing this disease, but most of people think of high cost and high risk. The objective of this study was estimate the cost of HSCT to compare the cost of hypertransfusion. We examined and calculated the direct costs of treatment in 37 children with Thalassemia underwent 6/6 HLA matchd related donor HSCT at Ramathibodi hospital between 1992 and 2008. A median time of follow-up was 15 months (1.8-63.6 months). The direct costs included the expenses of pre HSCT evaluation, admission for HSCT, complications and other related procedures for out patient follow-up until stopped immuno suppressive agents. Our datas demonstrated that the cost of HSCT was 957,008 THB per transplant which lower than hypertransfusion. Thirty-five patients are disease free survival (95%), being as normal life.
Department of Health, Thalassemia Foundation of Thailand, National Health Security Office. Problem situation "Thalassemia" in Thailand, Thalassemia 13th National Conference 2007 and Thalassemia National Plans, 2007-2011, October 3-5, 2007. Miracle Hotel Grand Bangkok: Pages 5-9.
Tangcharoensathien, V., Jongudomsuk, P. From policy to implementation: Historical events during 2001-2004 of universal coverage in Thailand. Nonthaburi: National Health Security Office 2004.
Towse A, Mills A, Tangcharoensathien V. Learning from Thailand's health reforms. BMJ. 2004;328:103-5.
Tanphaichitr V. The treatment of patients with Thalassemia. In: Lepnak T, Fucharoen S, Fucharoen P, Siritanarakul N, Tanphaichitr V, eds. Thalassemia : from molecular biology to clinical medicine. Nonthaburi: The Agriculture Cooperative of Thailand; 2005:128-35.
Gottschall J. Blood components. In: Friedman KD, King K, Nguyen KA, Pomper G, Sesok-Pizzini D, Wu Y, editors. Blood transfusion therapy, A physicianûs handbook. 8thed. Maryland: AABB; 2005. p.1-30.
Lanzkowsky P. Hemolytic anemia. In: Manual of pediatric hematology and oncology, 4thed. New York: Elsevier Inc; 2005. p.181-8.
Hsich MM, Tisdale JF, Rodgers GP. Hemolytic Anemia: Thalassemia and sickle cell disorder. In: Rodgers GP, Young NS, editors. The Bethesda Handbook of Clinical Hematology. 2nded. Philadelphia: Lippincort Williams & Wilkins; 2010. p.35-55.
Forget BG, Cohen PR. Thalassemia syndromes. In: Hoffman R, Benz Jr EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology basic principles and practice, 4th ed. Philadelphia: Elsevier Inc; 2005. p.557-88.
Viprakasit V, Lee LC, Chong QT, Lin KH, Khuhapinant A. Iron chelation therapy in the management of thalassemia: the Asia perspectives. Int J Hematol. 2009;90:435-45.
Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. Inherited disorders of the hemoglobin. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease control priorities in developing countries 2nded. New york: The World Bank and Oxford University Press; 2008.
Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hemat Educ Program. 2010; 2010:456-62.
Lucarelli G, Gaziev J. Advances in the allogeneic transplantation of thalassemia. Blood Rev. 2008;22:53-63.
Cost analysis. In: Drummond FM, Sculpher JM, Torrance WG, OûBrien JB, Stoddart LG. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford Unviersity Press; 2005. p 57.